

Global Gene Therapy Viral Vector and Plasmid DNA Market Growth 2023-2029

<https://marketpublishers.com/r/GF96BE41D936EN.html>

Date: June 2023

Pages: 121

Price: US\$ 3,660.00 (Single User License)

ID: GF96BE41D936EN

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

The global Gene Therapy Viral Vector and Plasmid DNA market size is projected to grow from US\$ million in 2022 to US\$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

United States market for Gene Therapy Viral Vector and Plasmid DNA is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Gene Therapy Viral Vector and Plasmid DNA is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Gene Therapy Viral Vector and Plasmid DNA is estimated to increase from US\$ million in 2022 to US\$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Gene Therapy Viral Vector and Plasmid DNA players cover Lonza, Merck KGaA, Thermo Fisher Scientific, Charles River Laboratories, Catalent, WuXi AppTec, FUJIFILM, GenScript Biotech and Takara Bio, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

Viral vector and plasmid DNA are tools to transfer genetic material into cells. Viral vectors are generally utilized as vectors for gene therapy. There are various types of vectors, such as lentivirus, adenovirus, adeno-associated virus (AAV), and others,

which include herpes simplex virus and chimeric viral vectors.

LPI (LP Information)' newest research report, the “Gene Therapy Viral Vector and Plasmid DNA Industry Forecast” looks at past sales and reviews total world Gene Therapy Viral Vector and Plasmid DNA sales in 2022, providing a comprehensive analysis by region and market sector of projected Gene Therapy Viral Vector and Plasmid DNA sales for 2023 through 2029. With Gene Therapy Viral Vector and Plasmid DNA sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US\$ millions of the world Gene Therapy Viral Vector and Plasmid DNA industry.

This Insight Report provides a comprehensive analysis of the global Gene Therapy Viral Vector and Plasmid DNA landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Gene Therapy Viral Vector and Plasmid DNA portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Gene Therapy Viral Vector and Plasmid DNA market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Gene Therapy Viral Vector and Plasmid DNA and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Gene Therapy Viral Vector and Plasmid DNA.

This report presents a comprehensive overview, market shares, and growth opportunities of Gene Therapy Viral Vector and Plasmid DNA market by product type, application, key manufacturers and key regions and countries.

Market Segmentation:

Segmentation by type

Viral Vectors

Plasmid DNA

Segmentation by application

Cell and Gene Therapy

Vaccine Development

Research

This report also splits the market by region:

Americas

United States

Canada

Mexico

Brazil

APAC

China

Japan

Korea

Southeast Asia

India

Australia

Europe

Germany

France

UK

Italy

Russia

Middle East & Africa

Egypt

South Africa

Israel

Turkey

GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

Lonza

Merck KGaA

Thermo Fisher Scientific

Charles River Laboratories

Catalent

WuXi AppTec

FUJIFILM

GenScript Biotech

Takara Bio

Oxford Biomedica

Novartis

Precision Biosciences

Bluebird Bio

Sartorius AG

Danaher

SIRON Biotech

VGXI

Waisman Biomanufacturing

Kaneka Eurogentec

PlasmidFactory

ATUM

Addgene

Cell and Gene Therapy Catapult

Batavia biosciences

Altogen Biosystems

Key Questions Addressed in this Report

What is the 10-year outlook for the global Gene Therapy Viral Vector and Plasmid DNA market?

What factors are driving Gene Therapy Viral Vector and Plasmid DNA market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Gene Therapy Viral Vector and Plasmid DNA market opportunities vary by end market size?

How does Gene Therapy Viral Vector and Plasmid DNA break out type, application?

What are the influences of COVID-19 and Russia-Ukraine war?

Contents

1 SCOPE OF THE REPORT

- 1.1 Market Introduction
- 1.2 Years Considered
- 1.3 Research Objectives
- 1.4 Market Research Methodology
- 1.5 Research Process and Data Source
- 1.6 Economic Indicators
- 1.7 Currency Considered
- 1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview

- 2.1.1 Global Gene Therapy Viral Vector and Plasmid DNA Annual Sales 2018-2029
- 2.1.2 World Current & Future Analysis for Gene Therapy Viral Vector and Plasmid DNA by Geographic Region, 2018, 2022 & 2029
- 2.1.3 World Current & Future Analysis for Gene Therapy Viral Vector and Plasmid DNA by Country/Region, 2018, 2022 & 2029
- 2.2 Gene Therapy Viral Vector and Plasmid DNA Segment by Type
 - 2.2.1 Viral Vectors
 - 2.2.2 Plasmid DNA
- 2.3 Gene Therapy Viral Vector and Plasmid DNA Sales by Type
 - 2.3.1 Global Gene Therapy Viral Vector and Plasmid DNA Sales Market Share by Type (2018-2023)
 - 2.3.2 Global Gene Therapy Viral Vector and Plasmid DNA Revenue and Market Share by Type (2018-2023)
 - 2.3.3 Global Gene Therapy Viral Vector and Plasmid DNA Sale Price by Type (2018-2023)
- 2.4 Gene Therapy Viral Vector and Plasmid DNA Segment by Application
 - 2.4.1 Cell and Gene Therapy
 - 2.4.2 Vaccine Development
 - 2.4.3 Research
- 2.5 Gene Therapy Viral Vector and Plasmid DNA Sales by Application
 - 2.5.1 Global Gene Therapy Viral Vector and Plasmid DNA Sale Market Share by Application (2018-2023)
 - 2.5.2 Global Gene Therapy Viral Vector and Plasmid DNA Revenue and Market Share

by Application (2018-2023)

2.5.3 Global Gene Therapy Viral Vector and Plasmid DNA Sale Price by Application (2018-2023)

3 GLOBAL GENE THERAPY VIRAL VECTOR AND PLASMID DNA BY COMPANY

3.1 Global Gene Therapy Viral Vector and Plasmid DNA Breakdown Data by Company

3.1.1 Global Gene Therapy Viral Vector and Plasmid DNA Annual Sales by Company (2018-2023)

3.1.2 Global Gene Therapy Viral Vector and Plasmid DNA Sales Market Share by Company (2018-2023)

3.2 Global Gene Therapy Viral Vector and Plasmid DNA Annual Revenue by Company (2018-2023)

3.2.1 Global Gene Therapy Viral Vector and Plasmid DNA Revenue by Company (2018-2023)

3.2.2 Global Gene Therapy Viral Vector and Plasmid DNA Revenue Market Share by Company (2018-2023)

3.3 Global Gene Therapy Viral Vector and Plasmid DNA Sale Price by Company

3.4 Key Manufacturers Gene Therapy Viral Vector and Plasmid DNA Producing Area Distribution, Sales Area, Product Type

3.4.1 Key Manufacturers Gene Therapy Viral Vector and Plasmid DNA Product Location Distribution

3.4.2 Players Gene Therapy Viral Vector and Plasmid DNA Products Offered

3.5 Market Concentration Rate Analysis

3.5.1 Competition Landscape Analysis

3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)

3.6 New Products and Potential Entrants

3.7 Mergers & Acquisitions, Expansion

4 WORLD HISTORIC REVIEW FOR GENE THERAPY VIRAL VECTOR AND PLASMID DNA BY GEOGRAPHIC REGION

4.1 World Historic Gene Therapy Viral Vector and Plasmid DNA Market Size by Geographic Region (2018-2023)

4.1.1 Global Gene Therapy Viral Vector and Plasmid DNA Annual Sales by Geographic Region (2018-2023)

4.1.2 Global Gene Therapy Viral Vector and Plasmid DNA Annual Revenue by Geographic Region (2018-2023)

4.2 World Historic Gene Therapy Viral Vector and Plasmid DNA Market Size by

Country/Region (2018-2023)

4.2.1 Global Gene Therapy Viral Vector and Plasmid DNA Annual Sales by Country/Region (2018-2023)

4.2.2 Global Gene Therapy Viral Vector and Plasmid DNA Annual Revenue by Country/Region (2018-2023)

4.3 Americas Gene Therapy Viral Vector and Plasmid DNA Sales Growth

4.4 APAC Gene Therapy Viral Vector and Plasmid DNA Sales Growth

4.5 Europe Gene Therapy Viral Vector and Plasmid DNA Sales Growth

4.6 Middle East & Africa Gene Therapy Viral Vector and Plasmid DNA Sales Growth

5 AMERICAS

5.1 Americas Gene Therapy Viral Vector and Plasmid DNA Sales by Country

5.1.1 Americas Gene Therapy Viral Vector and Plasmid DNA Sales by Country (2018-2023)

5.1.2 Americas Gene Therapy Viral Vector and Plasmid DNA Revenue by Country (2018-2023)

5.2 Americas Gene Therapy Viral Vector and Plasmid DNA Sales by Type

5.3 Americas Gene Therapy Viral Vector and Plasmid DNA Sales by Application

5.4 United States

5.5 Canada

5.6 Mexico

5.7 Brazil

6 APAC

6.1 APAC Gene Therapy Viral Vector and Plasmid DNA Sales by Region

6.1.1 APAC Gene Therapy Viral Vector and Plasmid DNA Sales by Region (2018-2023)

6.1.2 APAC Gene Therapy Viral Vector and Plasmid DNA Revenue by Region (2018-2023)

6.2 APAC Gene Therapy Viral Vector and Plasmid DNA Sales by Type

6.3 APAC Gene Therapy Viral Vector and Plasmid DNA Sales by Application

6.4 China

6.5 Japan

6.6 South Korea

6.7 Southeast Asia

6.8 India

6.9 Australia

6.10 China Taiwan

7 EUROPE

7.1 Europe Gene Therapy Viral Vector and Plasmid DNA by Country

7.1.1 Europe Gene Therapy Viral Vector and Plasmid DNA Sales by Country
(2018-2023)

7.1.2 Europe Gene Therapy Viral Vector and Plasmid DNA Revenue by Country
(2018-2023)

7.2 Europe Gene Therapy Viral Vector and Plasmid DNA Sales by Type

7.3 Europe Gene Therapy Viral Vector and Plasmid DNA Sales by Application

7.4 Germany

7.5 France

7.6 UK

7.7 Italy

7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa Gene Therapy Viral Vector and Plasmid DNA by Country

8.1.1 Middle East & Africa Gene Therapy Viral Vector and Plasmid DNA Sales by
Country (2018-2023)

8.1.2 Middle East & Africa Gene Therapy Viral Vector and Plasmid DNA Revenue by
Country (2018-2023)

8.2 Middle East & Africa Gene Therapy Viral Vector and Plasmid DNA Sales by Type

8.3 Middle East & Africa Gene Therapy Viral Vector and Plasmid DNA Sales by
Application

8.4 Egypt

8.5 South Africa

8.6 Israel

8.7 Turkey

8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities

9.2 Market Challenges & Risks

9.3 Industry Trends

10 MANUFACTURING COST STRUCTURE ANALYSIS

10.1 Raw Material and Suppliers

10.2 Manufacturing Cost Structure Analysis of Gene Therapy Viral Vector and Plasmid DNA

10.3 Manufacturing Process Analysis of Gene Therapy Viral Vector and Plasmid DNA

10.4 Industry Chain Structure of Gene Therapy Viral Vector and Plasmid DNA

11 MARKETING, DISTRIBUTORS AND CUSTOMER

11.1 Sales Channel

11.1.1 Direct Channels

11.1.2 Indirect Channels

11.2 Gene Therapy Viral Vector and Plasmid DNA Distributors

11.3 Gene Therapy Viral Vector and Plasmid DNA Customer

12 WORLD FORECAST REVIEW FOR GENE THERAPY VIRAL VECTOR AND PLASMID DNA BY GEOGRAPHIC REGION

12.1 Global Gene Therapy Viral Vector and Plasmid DNA Market Size Forecast by Region

12.1.1 Global Gene Therapy Viral Vector and Plasmid DNA Forecast by Region (2024-2029)

12.1.2 Global Gene Therapy Viral Vector and Plasmid DNA Annual Revenue Forecast by Region (2024-2029)

12.2 Americas Forecast by Country

12.3 APAC Forecast by Region

12.4 Europe Forecast by Country

12.5 Middle East & Africa Forecast by Country

12.6 Global Gene Therapy Viral Vector and Plasmid DNA Forecast by Type

12.7 Global Gene Therapy Viral Vector and Plasmid DNA Forecast by Application

13 KEY PLAYERS ANALYSIS

13.1 Lonza

13.1.1 Lonza Company Information

13.1.2 Lonza Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications

13.1.3 Lonza Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue, Price and

Gross Margin (2018-2023)

13.1.4 Lonza Main Business Overview

13.1.5 Lonza Latest Developments

13.2 Merck KGaA

13.2.1 Merck KGaA Company Information

13.2.2 Merck KGaA Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications

13.2.3 Merck KGaA Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue, Price and Gross Margin (2018-2023)

13.2.4 Merck KGaA Main Business Overview

13.2.5 Merck KGaA Latest Developments

13.3 Thermo Fisher Scientific

13.3.1 Thermo Fisher Scientific Company Information

13.3.2 Thermo Fisher Scientific Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications

13.3.3 Thermo Fisher Scientific Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue, Price and Gross Margin (2018-2023)

13.3.4 Thermo Fisher Scientific Main Business Overview

13.3.5 Thermo Fisher Scientific Latest Developments

13.4 Charles River Laboratories

13.4.1 Charles River Laboratories Company Information

13.4.2 Charles River Laboratories Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications

13.4.3 Charles River Laboratories Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue, Price and Gross Margin (2018-2023)

13.4.4 Charles River Laboratories Main Business Overview

13.4.5 Charles River Laboratories Latest Developments

13.5 Catalent

13.5.1 Catalent Company Information

13.5.2 Catalent Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications

13.5.3 Catalent Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue, Price and Gross Margin (2018-2023)

13.5.4 Catalent Main Business Overview

13.5.5 Catalent Latest Developments

13.6 WuXi AppTec

13.6.1 WuXi AppTec Company Information

13.6.2 WuXi AppTec Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications

13.6.3 WuXi AppTec Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue, Price and Gross Margin (2018-2023)

13.6.4 WuXi AppTec Main Business Overview

13.6.5 WuXi AppTec Latest Developments

13.7 FUJIFILM

13.7.1 FUJIFILM Company Information

13.7.2 FUJIFILM Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications

13.7.3 FUJIFILM Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue, Price and Gross Margin (2018-2023)

13.7.4 FUJIFILM Main Business Overview

13.7.5 FUJIFILM Latest Developments

13.8 GenScript Biotech

13.8.1 GenScript Biotech Company Information

13.8.2 GenScript Biotech Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications

13.8.3 GenScript Biotech Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue, Price and Gross Margin (2018-2023)

13.8.4 GenScript Biotech Main Business Overview

13.8.5 GenScript Biotech Latest Developments

13.9 Takara Bio

13.9.1 Takara Bio Company Information

13.9.2 Takara Bio Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications

13.9.3 Takara Bio Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue, Price and Gross Margin (2018-2023)

13.9.4 Takara Bio Main Business Overview

13.9.5 Takara Bio Latest Developments

13.10 Oxford Biomedica

13.10.1 Oxford Biomedica Company Information

13.10.2 Oxford Biomedica Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications

13.10.3 Oxford Biomedica Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue, Price and Gross Margin (2018-2023)

13.10.4 Oxford Biomedica Main Business Overview

13.10.5 Oxford Biomedica Latest Developments

13.11 Novartis

13.11.1 Novartis Company Information

13.11.2 Novartis Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and

Specifications

13.11.3 Novartis Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue, Price and Gross Margin (2018-2023)

13.11.4 Novartis Main Business Overview

13.11.5 Novartis Latest Developments

13.12 Precision Biosciences

13.12.1 Precision Biosciences Company Information

13.12.2 Precision Biosciences Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications

13.12.3 Precision Biosciences Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue, Price and Gross Margin (2018-2023)

13.12.4 Precision Biosciences Main Business Overview

13.12.5 Precision Biosciences Latest Developments

13.13 Bluebird Bio

13.13.1 Bluebird Bio Company Information

13.13.2 Bluebird Bio Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications

13.13.3 Bluebird Bio Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue, Price and Gross Margin (2018-2023)

13.13.4 Bluebird Bio Main Business Overview

13.13.5 Bluebird Bio Latest Developments

13.14 Sartorius AG

13.14.1 Sartorius AG Company Information

13.14.2 Sartorius AG Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications

13.14.3 Sartorius AG Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue, Price and Gross Margin (2018-2023)

13.14.4 Sartorius AG Main Business Overview

13.14.5 Sartorius AG Latest Developments

13.15 Danaher

13.15.1 Danaher Company Information

13.15.2 Danaher Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications

13.15.3 Danaher Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue, Price and Gross Margin (2018-2023)

13.15.4 Danaher Main Business Overview

13.15.5 Danaher Latest Developments

13.16 SIRON Biotech

13.16.1 SIRON Biotech Company Information

- 13.16.2 SIRON Biotech Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
 - 13.16.3 SIRON Biotech Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.16.4 SIRON Biotech Main Business Overview
 - 13.16.5 SIRON Biotech Latest Developments
- 13.17 VGXI
 - 13.17.1 VGXI Company Information
 - 13.17.2 VGXI Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
 - 13.17.3 VGXI Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.17.4 VGXI Main Business Overview
 - 13.17.5 VGXI Latest Developments
- 13.18 Waisman Biomanufacturing
 - 13.18.1 Waisman Biomanufacturing Company Information
 - 13.18.2 Waisman Biomanufacturing Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
 - 13.18.3 Waisman Biomanufacturing Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.18.4 Waisman Biomanufacturing Main Business Overview
 - 13.18.5 Waisman Biomanufacturing Latest Developments
- 13.19 Kaneka Eurogentec
 - 13.19.1 Kaneka Eurogentec Company Information
 - 13.19.2 Kaneka Eurogentec Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
 - 13.19.3 Kaneka Eurogentec Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.19.4 Kaneka Eurogentec Main Business Overview
 - 13.19.5 Kaneka Eurogentec Latest Developments
- 13.20 PlasmidFactory
 - 13.20.1 PlasmidFactory Company Information
 - 13.20.2 PlasmidFactory Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
 - 13.20.3 PlasmidFactory Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.20.4 PlasmidFactory Main Business Overview
 - 13.20.5 PlasmidFactory Latest Developments
- 13.21 ATUM

- 13.21.1 ATUM Company Information
- 13.21.2 ATUM Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
- 13.21.3 ATUM Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue, Price and Gross Margin (2018-2023)
- 13.21.4 ATUM Main Business Overview
- 13.21.5 ATUM Latest Developments
- 13.22 Addgene
 - 13.22.1 Addgene Company Information
 - 13.22.2 Addgene Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
 - 13.22.3 Addgene Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.22.4 Addgene Main Business Overview
 - 13.22.5 Addgene Latest Developments
- 13.23 Cell and Gene Therapy Catapult
 - 13.23.1 Cell and Gene Therapy Catapult Company Information
 - 13.23.2 Cell and Gene Therapy Catapult Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
 - 13.23.3 Cell and Gene Therapy Catapult Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.23.4 Cell and Gene Therapy Catapult Main Business Overview
 - 13.23.5 Cell and Gene Therapy Catapult Latest Developments
- 13.24 Batavia biosciences
 - 13.24.1 Batavia biosciences Company Information
 - 13.24.2 Batavia biosciences Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
 - 13.24.3 Batavia biosciences Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.24.4 Batavia biosciences Main Business Overview
 - 13.24.5 Batavia biosciences Latest Developments
- 13.25 Altogen Biosystems
 - 13.25.1 Altogen Biosystems Company Information
 - 13.25.2 Altogen Biosystems Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
 - 13.25.3 Altogen Biosystems Gene Therapy Viral Vector and Plasmid DNA Sales, Revenue, Price and Gross Margin (2018-2023)
 - 13.25.4 Altogen Biosystems Main Business Overview
 - 13.25.5 Altogen Biosystems Latest Developments

14 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. Gene Therapy Viral Vector and Plasmid DNA Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & (\$ millions)

Table 2. Gene Therapy Viral Vector and Plasmid DNA Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & (\$ millions)

Table 3. Major Players of Viral Vectors

Table 4. Major Players of Plasmid DNA

Table 5. Global Gene Therapy Viral Vector and Plasmid DNA Sales by Type (2018-2023) & (K Units)

Table 6. Global Gene Therapy Viral Vector and Plasmid DNA Sales Market Share by Type (2018-2023)

Table 7. Global Gene Therapy Viral Vector and Plasmid DNA Revenue by Type (2018-2023) & (\$ million)

Table 8. Global Gene Therapy Viral Vector and Plasmid DNA Revenue Market Share by Type (2018-2023)

Table 9. Global Gene Therapy Viral Vector and Plasmid DNA Sale Price by Type (2018-2023) & (US\$/Unit)

Table 10. Global Gene Therapy Viral Vector and Plasmid DNA Sales by Application (2018-2023) & (K Units)

Table 11. Global Gene Therapy Viral Vector and Plasmid DNA Sales Market Share by Application (2018-2023)

Table 12. Global Gene Therapy Viral Vector and Plasmid DNA Revenue by Application (2018-2023)

Table 13. Global Gene Therapy Viral Vector and Plasmid DNA Revenue Market Share by Application (2018-2023)

Table 14. Global Gene Therapy Viral Vector and Plasmid DNA Sale Price by Application (2018-2023) & (US\$/Unit)

Table 15. Global Gene Therapy Viral Vector and Plasmid DNA Sales by Company (2018-2023) & (K Units)

Table 16. Global Gene Therapy Viral Vector and Plasmid DNA Sales Market Share by Company (2018-2023)

Table 17. Global Gene Therapy Viral Vector and Plasmid DNA Revenue by Company (2018-2023) (\$ Millions)

Table 18. Global Gene Therapy Viral Vector and Plasmid DNA Revenue Market Share by Company (2018-2023)

Table 19. Global Gene Therapy Viral Vector and Plasmid DNA Sale Price by Company

(2018-2023) & (US\$/Unit)

Table 20. Key Manufacturers Gene Therapy Viral Vector and Plasmid DNA Producing Area Distribution and Sales Area

Table 21. Players Gene Therapy Viral Vector and Plasmid DNA Products Offered

Table 22. Gene Therapy Viral Vector and Plasmid DNA Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)

Table 23. New Products and Potential Entrants

Table 24. Mergers & Acquisitions, Expansion

Table 25. Global Gene Therapy Viral Vector and Plasmid DNA Sales by Geographic Region (2018-2023) & (K Units)

Table 26. Global Gene Therapy Viral Vector and Plasmid DNA Sales Market Share Geographic Region (2018-2023)

Table 27. Global Gene Therapy Viral Vector and Plasmid DNA Revenue by Geographic Region (2018-2023) & (\$ millions)

Table 28. Global Gene Therapy Viral Vector and Plasmid DNA Revenue Market Share by Geographic Region (2018-2023)

Table 29. Global Gene Therapy Viral Vector and Plasmid DNA Sales by Country/Region (2018-2023) & (K Units)

Table 30. Global Gene Therapy Viral Vector and Plasmid DNA Sales Market Share by Country/Region (2018-2023)

Table 31. Global Gene Therapy Viral Vector and Plasmid DNA Revenue by Country/Region (2018-2023) & (\$ millions)

Table 32. Global Gene Therapy Viral Vector and Plasmid DNA Revenue Market Share by Country/Region (2018-2023)

Table 33. Americas Gene Therapy Viral Vector and Plasmid DNA Sales by Country (2018-2023) & (K Units)

Table 34. Americas Gene Therapy Viral Vector and Plasmid DNA Sales Market Share by Country (2018-2023)

Table 35. Americas Gene Therapy Viral Vector and Plasmid DNA Revenue by Country (2018-2023) & (\$ Millions)

Table 36. Americas Gene Therapy Viral Vector and Plasmid DNA Revenue Market Share by Country (2018-2023)

Table 37. Americas Gene Therapy Viral Vector and Plasmid DNA Sales by Type (2018-2023) & (K Units)

Table 38. Americas Gene Therapy Viral Vector and Plasmid DNA Sales by Application (2018-2023) & (K Units)

Table 39. APAC Gene Therapy Viral Vector and Plasmid DNA Sales by Region (2018-2023) & (K Units)

Table 40. APAC Gene Therapy Viral Vector and Plasmid DNA Sales Market Share by

Region (2018-2023)

Table 41. APAC Gene Therapy Viral Vector and Plasmid DNA Revenue by Region (2018-2023) & (\$ Millions)

Table 42. APAC Gene Therapy Viral Vector and Plasmid DNA Revenue Market Share by Region (2018-2023)

Table 43. APAC Gene Therapy Viral Vector and Plasmid DNA Sales by Type (2018-2023) & (K Units)

Table 44. APAC Gene Therapy Viral Vector and Plasmid DNA Sales by Application (2018-2023) & (K Units)

Table 45. Europe Gene Therapy Viral Vector and Plasmid DNA Sales by Country (2018-2023) & (K Units)

Table 46. Europe Gene Therapy Viral Vector and Plasmid DNA Sales Market Share by Country (2018-2023)

Table 47. Europe Gene Therapy Viral Vector and Plasmid DNA Revenue by Country (2018-2023) & (\$ Millions)

Table 48. Europe Gene Therapy Viral Vector and Plasmid DNA Revenue Market Share by Country (2018-2023)

Table 49. Europe Gene Therapy Viral Vector and Plasmid DNA Sales by Type (2018-2023) & (K Units)

Table 50. Europe Gene Therapy Viral Vector and Plasmid DNA Sales by Application (2018-2023) & (K Units)

Table 51. Middle East & Africa Gene Therapy Viral Vector and Plasmid DNA Sales by Country (2018-2023) & (K Units)

Table 52. Middle East & Africa Gene Therapy Viral Vector and Plasmid DNA Sales Market Share by Country (2018-2023)

Table 53. Middle East & Africa Gene Therapy Viral Vector and Plasmid DNA Revenue by Country (2018-2023) & (\$ Millions)

Table 54. Middle East & Africa Gene Therapy Viral Vector and Plasmid DNA Revenue Market Share by Country (2018-2023)

Table 55. Middle East & Africa Gene Therapy Viral Vector and Plasmid DNA Sales by Type (2018-2023) & (K Units)

Table 56. Middle East & Africa Gene Therapy Viral Vector and Plasmid DNA Sales by Application (2018-2023) & (K Units)

Table 57. Key Market Drivers & Growth Opportunities of Gene Therapy Viral Vector and Plasmid DNA

Table 58. Key Market Challenges & Risks of Gene Therapy Viral Vector and Plasmid DNA

Table 59. Key Industry Trends of Gene Therapy Viral Vector and Plasmid DNA

Table 60. Gene Therapy Viral Vector and Plasmid DNA Raw Material

- Table 61. Key Suppliers of Raw Materials
- Table 62. Gene Therapy Viral Vector and Plasmid DNA Distributors List
- Table 63. Gene Therapy Viral Vector and Plasmid DNA Customer List
- Table 64. Global Gene Therapy Viral Vector and Plasmid DNA Sales Forecast by Region (2024-2029) & (K Units)
- Table 65. Global Gene Therapy Viral Vector and Plasmid DNA Revenue Forecast by Region (2024-2029) & (\$ millions)
- Table 66. Americas Gene Therapy Viral Vector and Plasmid DNA Sales Forecast by Country (2024-2029) & (K Units)
- Table 67. Americas Gene Therapy Viral Vector and Plasmid DNA Revenue Forecast by Country (2024-2029) & (\$ millions)
- Table 68. APAC Gene Therapy Viral Vector and Plasmid DNA Sales Forecast by Region (2024-2029) & (K Units)
- Table 69. APAC Gene Therapy Viral Vector and Plasmid DNA Revenue Forecast by Region (2024-2029) & (\$ millions)
- Table 70. Europe Gene Therapy Viral Vector and Plasmid DNA Sales Forecast by Country (2024-2029) & (K Units)
- Table 71. Europe Gene Therapy Viral Vector and Plasmid DNA Revenue Forecast by Country (2024-2029) & (\$ millions)
- Table 72. Middle East & Africa Gene Therapy Viral Vector and Plasmid DNA Sales Forecast by Country (2024-2029) & (K Units)
- Table 73. Middle East & Africa Gene Therapy Viral Vector and Plasmid DNA Revenue Forecast by Country (2024-2029) & (\$ millions)
- Table 74. Global Gene Therapy Viral Vector and Plasmid DNA Sales Forecast by Type (2024-2029) & (K Units)
- Table 75. Global Gene Therapy Viral Vector and Plasmid DNA Revenue Forecast by Type (2024-2029) & (\$ Millions)
- Table 76. Global Gene Therapy Viral Vector and Plasmid DNA Sales Forecast by Application (2024-2029) & (K Units)
- Table 77. Global Gene Therapy Viral Vector and Plasmid DNA Revenue Forecast by Application (2024-2029) & (\$ Millions)
- Table 78. Lonza Basic Information, Gene Therapy Viral Vector and Plasmid DNA Manufacturing Base, Sales Area and Its Competitors
- Table 79. Lonza Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications
- Table 80. Lonza Gene Therapy Viral Vector and Plasmid DNA Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)
- Table 81. Lonza Main Business
- Table 82. Lonza Latest Developments

Table 83. Merck KGaA Basic Information, Gene Therapy Viral Vector and Plasmid DNA Manufacturing Base, Sales Area and Its Competitors

Table 84. Merck KGaA Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications

Table 85. Merck KGaA Gene Therapy Viral Vector and Plasmid DNA Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 86. Merck KGaA Main Business

Table 87. Merck KGaA Latest Developments

Table 88. Thermo Fisher Scientific Basic Information, Gene Therapy Viral Vector and Plasmid DNA Manufacturing Base, Sales Area and Its Competitors

Table 89. Thermo Fisher Scientific Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications

Table 90. Thermo Fisher Scientific Gene Therapy Viral Vector and Plasmid DNA Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 91. Thermo Fisher Scientific Main Business

Table 92. Thermo Fisher Scientific Latest Developments

Table 93. Charles River Laboratories Basic Information, Gene Therapy Viral Vector and Plasmid DNA Manufacturing Base, Sales Area and Its Competitors

Table 94. Charles River Laboratories Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications

Table 95. Charles River Laboratories Gene Therapy Viral Vector and Plasmid DNA Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 96. Charles River Laboratories Main Business

Table 97. Charles River Laboratories Latest Developments

Table 98. Catalent Basic Information, Gene Therapy Viral Vector and Plasmid DNA Manufacturing Base, Sales Area and Its Competitors

Table 99. Catalent Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications

Table 100. Catalent Gene Therapy Viral Vector and Plasmid DNA Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 101. Catalent Main Business

Table 102. Catalent Latest Developments

Table 103. WuXi AppTec Basic Information, Gene Therapy Viral Vector and Plasmid DNA Manufacturing Base, Sales Area and Its Competitors

Table 104. WuXi AppTec Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications

Table 105. WuXi AppTec Gene Therapy Viral Vector and Plasmid DNA Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 106. WuXi AppTec Main Business

Table 107. WuXi AppTec Latest Developments

Table 108. FUJIFILM Basic Information, Gene Therapy Viral Vector and Plasmid DNA Manufacturing Base, Sales Area and Its Competitors

Table 109. FUJIFILM Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications

Table 110. FUJIFILM Gene Therapy Viral Vector and Plasmid DNA Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 111. FUJIFILM Main Business

Table 112. FUJIFILM Latest Developments

Table 113. GenScript Biotech Basic Information, Gene Therapy Viral Vector and Plasmid DNA Manufacturing Base, Sales Area and Its Competitors

Table 114. GenScript Biotech Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications

Table 115. GenScript Biotech Gene Therapy Viral Vector and Plasmid DNA Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 116. GenScript Biotech Main Business

Table 117. GenScript Biotech Latest Developments

Table 118. Takara Bio Basic Information, Gene Therapy Viral Vector and Plasmid DNA Manufacturing Base, Sales Area and Its Competitors

Table 119. Takara Bio Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications

Table 120. Takara Bio Gene Therapy Viral Vector and Plasmid DNA Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 121. Takara Bio Main Business

Table 122. Takara Bio Latest Developments

Table 123. Oxford Biomedica Basic Information, Gene Therapy Viral Vector and Plasmid DNA Manufacturing Base, Sales Area and Its Competitors

Table 124. Oxford Biomedica Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications

Table 125. Oxford Biomedica Gene Therapy Viral Vector and Plasmid DNA Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 126. Oxford Biomedica Main Business

Table 127. Oxford Biomedica Latest Developments

Table 128. Novartis Basic Information, Gene Therapy Viral Vector and Plasmid DNA Manufacturing Base, Sales Area and Its Competitors

Table 129. Novartis Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications

Table 130. Novartis Gene Therapy Viral Vector and Plasmid DNA Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 131. Novartis Main Business

Table 132. Novartis Latest Developments

Table 133. Precision Biosciences Basic Information, Gene Therapy Viral Vector and Plasmid DNA Manufacturing Base, Sales Area and Its Competitors

Table 134. Precision Biosciences Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications

Table 135. Precision Biosciences Gene Therapy Viral Vector and Plasmid DNA Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 136. Precision Biosciences Main Business

Table 137. Precision Biosciences Latest Developments

Table 138. Bluebird Bio Basic Information, Gene Therapy Viral Vector and Plasmid DNA Manufacturing Base, Sales Area and Its Competitors

Table 139. Bluebird Bio Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications

Table 140. Bluebird Bio Gene Therapy Viral Vector and Plasmid DNA Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 141. Bluebird Bio Main Business

Table 142. Bluebird Bio Latest Developments

Table 143. Sartorius AG Basic Information, Gene Therapy Viral Vector and Plasmid DNA Manufacturing Base, Sales Area and Its Competitors

Table 144. Sartorius AG Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications

Table 145. Sartorius AG Gene Therapy Viral Vector and Plasmid DNA Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 146. Sartorius AG Main Business

Table 147. Sartorius AG Latest Developments

Table 148. Danaher Basic Information, Gene Therapy Viral Vector and Plasmid DNA Manufacturing Base, Sales Area and Its Competitors

Table 149. Danaher Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications

Table 150. Danaher Gene Therapy Viral Vector and Plasmid DNA Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 151. Danaher Main Business

Table 152. Danaher Latest Developments

Table 153. SIRON Biotech Basic Information, Gene Therapy Viral Vector and Plasmid DNA Manufacturing Base, Sales Area and Its Competitors

Table 154. SIRON Biotech Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications

Table 155. SIRON Biotech Gene Therapy Viral Vector and Plasmid DNA Sales (K

Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 156. SIRON Biotech Main Business

Table 157. SIRON Biotech Latest Developments

Table 158. VGXI Basic Information, Gene Therapy Viral Vector and Plasmid DNA Manufacturing Base, Sales Area and Its Competitors

Table 159. VGXI Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications

Table 160. VGXI Gene Therapy Viral Vector and Plasmid DNA Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 161. VGXI Main Business

Table 162. VGXI Latest Developments

Table 163. Waisman Biomanufacturing Basic Information, Gene Therapy Viral Vector and Plasmid DNA Manufacturing Base, Sales Area and Its Competitors

Table 164. Waisman Biomanufacturing Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications

Table 165. Waisman Biomanufacturing Gene Therapy Viral Vector and Plasmid DNA Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 166. Waisman Biomanufacturing Main Business

Table 167. Waisman Biomanufacturing Latest Developments

Table 168. Kaneka Eurogentec Basic Information, Gene Therapy Viral Vector and Plasmid DNA Manufacturing Base, Sales Area and Its Competitors

Table 169. Kaneka Eurogentec Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications

Table 170. Kaneka Eurogentec Gene Therapy Viral Vector and Plasmid DNA Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 171. Kaneka Eurogentec Main Business

Table 172. Kaneka Eurogentec Latest Developments

Table 173. PlasmidFactory Basic Information, Gene Therapy Viral Vector and Plasmid DNA Manufacturing Base, Sales Area and Its Competitors

Table 174. PlasmidFactory Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications

Table 175. PlasmidFactory Gene Therapy Viral Vector and Plasmid DNA Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 176. PlasmidFactory Main Business

Table 177. PlasmidFactory Latest Developments

Table 178. ATUM Basic Information, Gene Therapy Viral Vector and Plasmid DNA Manufacturing Base, Sales Area and Its Competitors

Table 179. ATUM Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications

Table 180. ATUM Gene Therapy Viral Vector and Plasmid DNA Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 181. ATUM Main Business

Table 182. ATUM Latest Developments

Table 183. Addgene Basic Information, Gene Therapy Viral Vector and Plasmid DNA Manufacturing Base, Sales Area and Its Competitors

Table 184. Addgene Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications

Table 185. Addgene Gene Therapy Viral Vector and Plasmid DNA Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 186. Addgene Main Business

Table 187. Addgene Latest Developments

Table 188. Cell and Gene Therapy Catapult Basic Information, Gene Therapy Viral Vector and Plasmid DNA Manufacturing Base, Sales Area and Its Competitors

Table 189. Cell and Gene Therapy Catapult Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications

Table 190. Cell and Gene Therapy Catapult Gene Therapy Viral Vector and Plasmid DNA Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 191. Cell and Gene Therapy Catapult Main Business

Table 192. Cell and Gene Therapy Catapult Latest Developments

Table 193. Batavia biosciences Basic Information, Gene Therapy Viral Vector and Plasmid DNA Manufacturing Base, Sales Area and Its Competitors

Table 194. Batavia biosciences Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications

Table 195. Batavia biosciences Gene Therapy Viral Vector and Plasmid DNA Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 196. Batavia biosciences Main Business

Table 197. Batavia biosciences Latest Developments

Table 198. Altogen Biosystems Basic Information, Gene Therapy Viral Vector and Plasmid DNA Manufacturing Base, Sales Area and Its Competitors

Table 199. Altogen Biosystems Gene Therapy Viral Vector and Plasmid DNA Product Portfolios and Specifications

Table 200. Altogen Biosystems Gene Therapy Viral Vector and Plasmid DNA Sales (K Units), Revenue (\$ Million), Price (US\$/Unit) and Gross Margin (2018-2023)

Table 201. Altogen Biosystems Main Business

Table 202. Altogen Biosystems Latest Developments

List Of Figures

LIST OF FIGURES

- Figure 1. Picture of Gene Therapy Viral Vector and Plasmid DNA
- Figure 2. Gene Therapy Viral Vector and Plasmid DNA Report Years Considered
- Figure 3. Research Objectives
- Figure 4. Research Methodology
- Figure 5. Research Process and Data Source
- Figure 6. Global Gene Therapy Viral Vector and Plasmid DNA Sales Growth Rate 2018-2029 (K Units)
- Figure 7. Global Gene Therapy Viral Vector and Plasmid DNA Revenue Growth Rate 2018-2029 (\$ Millions)
- Figure 8. Gene Therapy Viral Vector and Plasmid DNA Sales by Region (2018, 2022 & 2029) & (\$ Millions)
- Figure 9. Product Picture of Viral Vectors
- Figure 10. Product Picture of Plasmid DNA
- Figure 11. Global Gene Therapy Viral Vector and Plasmid DNA Sales Market Share by Type in 2022
- Figure 12. Global Gene Therapy Viral Vector and Plasmid DNA Revenue Market Share by Type (2018-2023)
- Figure 13. Gene Therapy Viral Vector and Plasmid DNA Consumed in Cell and Gene Therapy
- Figure 14. Global Gene Therapy Viral Vector and Plasmid DNA Market: Cell and Gene Therapy (2018-2023) & (K Units)
- Figure 15. Gene Therapy Viral Vector and Plasmid DNA Consumed in Vaccine Development
- Figure 16. Global Gene Therapy Viral Vector and Plasmid DNA Market: Vaccine Development (2018-2023) & (K Units)
- Figure 17. Gene Therapy Viral Vector and Plasmid DNA Consumed in Research
- Figure 18. Global Gene Therapy Viral Vector and Plasmid DNA Market: Research (2018-2023) & (K Units)
- Figure 19. Global Gene Therapy Viral Vector and Plasmid DNA Sales Market Share by Application (2022)
- Figure 20. Global Gene Therapy Viral Vector and Plasmid DNA Revenue Market Share by Application in 2022
- Figure 21. Gene Therapy Viral Vector and Plasmid DNA Sales Market by Company in 2022 (K Units)
- Figure 22. Global Gene Therapy Viral Vector and Plasmid DNA Sales Market Share by

Company in 2022

Figure 23. Gene Therapy Viral Vector and Plasmid DNA Revenue Market by Company in 2022 (\$ Million)

Figure 24. Global Gene Therapy Viral Vector and Plasmid DNA Revenue Market Share by Company in 2022

Figure 25. Global Gene Therapy Viral Vector and Plasmid DNA Sales Market Share by Geographic Region (2018-2023)

Figure 26. Global Gene Therapy Viral Vector and Plasmid DNA Revenue Market Share by Geographic Region in 2022

Figure 27. Americas Gene Therapy Viral Vector and Plasmid DNA Sales 2018-2023 (K Units)

Figure 28. Americas Gene Therapy Viral Vector and Plasmid DNA Revenue 2018-2023 (\$ Millions)

Figure 29. APAC Gene Therapy Viral Vector and Plasmid DNA Sales 2018-2023 (K Units)

Figure 30. APAC Gene Therapy Viral Vector and Plasmid DNA Revenue 2018-2023 (\$ Millions)

Figure 31. Europe Gene Therapy Viral Vector and Plasmid DNA Sales 2018-2023 (K Units)

Figure 32. Europe Gene Therapy Viral Vector and Plasmid DNA Revenue 2018-2023 (\$ Millions)

Figure 33. Middle East & Africa Gene Therapy Viral Vector and Plasmid DNA Sales 2018-2023 (K Units)

Figure 34. Middle East & Africa Gene Therapy Viral Vector and Plasmid DNA Revenue 2018-2023 (\$ Millions)

Figure 35. Americas Gene Therapy Viral Vector and Plasmid DNA Sales Market Share by Country in 2022

Figure 36. Americas Gene Therapy Viral Vector and Plasmid DNA Revenue Market Share by Country in 2022

Figure 37. Americas Gene Therapy Viral Vector and Plasmid DNA Sales Market Share by Type (2018-2023)

Figure 38. Americas Gene Therapy Viral Vector and Plasmid DNA Sales Market Share by Application (2018-2023)

Figure 39. United States Gene Therapy Viral Vector and Plasmid DNA Revenue Growth 2018-2023 (\$ Millions)

Figure 40. Canada Gene Therapy Viral Vector and Plasmid DNA Revenue Growth 2018-2023 (\$ Millions)

Figure 41. Mexico Gene Therapy Viral Vector and Plasmid DNA Revenue Growth 2018-2023 (\$ Millions)

Figure 42. Brazil Gene Therapy Viral Vector and Plasmid DNA Revenue Growth 2018-2023 (\$ Millions)

Figure 43. APAC Gene Therapy Viral Vector and Plasmid DNA Sales Market Share by Region in 2022

Figure 44. APAC Gene Therapy Viral Vector and Plasmid DNA Revenue Market Share by Regions in 2022

Figure 45. APAC Gene Therapy Viral Vector and Plasmid DNA Sales Market Share by Type (2018-2023)

Figure 46. APAC Gene Therapy Viral Vector and Plasmid DNA Sales Market Share by Application (2018-2023)

Figure 47. China Gene Therapy Viral Vector and Plasmid DNA Revenue Growth 2018-2023 (\$ Millions)

Figure 48. Japan Gene Therapy Viral Vector and Plasmid DNA Revenue Growth 2018-2023 (\$ Millions)

Figure 49. South Korea Gene Therapy Viral Vector and Plasmid DNA Revenue Growth 2018-2023 (\$ Millions)

Figure 50. Southeast Asia Gene Therapy Viral Vector and Plasmid DNA Revenue Growth 2018-2023 (\$ Millions)

Figure 51. India Gene Therapy Viral Vector and Plasmid DNA Revenue Growth 2018-2023 (\$ Millions)

Figure 52. Australia Gene Therapy Viral Vector and Plasmid DNA Revenue Growth 2018-2023 (\$ Millions)

Figure 53. China Taiwan Gene Therapy Viral Vector and Plasmid DNA Revenue Growth 2018-2023 (\$ Millions)

Figure 54. Europe Gene Therapy Viral Vector and Plasmid DNA Sales Market Share by Country in 2022

Figure 55. Europe Gene Therapy Viral Vector and Plasmid DNA Revenue Market Share by Country in 2022

Figure 56. Europe Gene Therapy Viral Vector and Plasmid DNA Sales Market Share by Type (2018-2023)

Figure 57. Europe Gene Therapy Viral Vector and Plasmid DNA Sales Market Share by Application (2018-2023)

Figure 58. Germany Gene Therapy Viral Vector and Plasmid DNA Revenue Growth 2018-2023 (\$ Millions)

Figure 59. France Gene Therapy Viral Vector and Plasmid DNA Revenue Growth 2018-2023 (\$ Millions)

Figure 60. UK Gene Therapy Viral Vector and Plasmid DNA Revenue Growth 2018-2023 (\$ Millions)

Figure 61. Italy Gene Therapy Viral Vector and Plasmid DNA Revenue Growth

2018-2023 (\$ Millions)

Figure 62. Russia Gene Therapy Viral Vector and Plasmid DNA Revenue Growth

2018-2023 (\$ Millions)

Figure 63. Middle East & Africa Gene Therapy Viral Vector and Plasmid DNA Sales Market Share by Country in 2022

Figure 64. Middle East & Africa Gene Therapy Viral Vector and Plasmid DNA Revenue Market Share by Country in 2022

Figure 65. Middle East & Africa Gene Therapy Viral Vector and Plasmid DNA Sales Market Share by Type (2018-2023)

Figure 66. Middle East & Africa Gene Therapy Viral Vector and Plasmid DNA Sales Market Share by Application (2018-2023)

Figure 67. Egypt Gene Therapy Viral Vector and Plasmid DNA Revenue Growth 2018-2023 (\$ Millions)

Figure 68. South Africa Gene Therapy Viral Vector and Plasmid DNA Revenue Growth 2018-2023 (\$ Millions)

Figure 69. Israel Gene Therapy Viral Vector and Plasmid DNA Revenue Growth 2018-2023 (\$ Millions)

Figure 70. Turkey Gene Therapy Viral Vector and Plasmid DNA Revenue Growth 2018-2023 (\$ Millions)

Figure 71. GCC Country Gene Therapy Viral Vector and Plasmid DNA Revenue Growth 2018-2023 (\$ Millions)

Figure 72. Manufacturing Cost Structure Analysis of Gene Therapy Viral Vector and Plasmid DNA in 2022

Figure 73. Manufacturing Process Analysis of Gene Therapy Viral Vector and Plasmid DNA

Figure 74. Industry Chain Structure of Gene Therapy Viral Vector and Plasmid DNA

Figure 75. Channels of Distribution

Figure 76. Global Gene Therapy Viral Vector and Plasmid DNA Sales Market Forecast by Region (2024-2029)

Figure 77. Global Gene Therapy Viral Vector and Plasmid DNA Revenue Market Share Forecast by Region (2024-2029)

Figure 78. Global Gene Therapy Viral Vector and Plasmid DNA Sales Market Share Forecast by Type (2024-2029)

Figure 79. Global Gene Therapy Viral Vector and Plasmid DNA Revenue Market Share Forecast by Type (2024-2029)

Figure 80. Global Gene Therapy Viral Vector and Plasmid DNA Sales Market Share Forecast by Application (2024-2029)

Figure 81. Global Gene Therapy Viral Vector and Plasmid DNA Revenue Market Share Forecast by Application (2024-2029)

I would like to order

Product name: Global Gene Therapy Viral Vector and Plasmid DNA Market Growth 2023-2029

Product link: <https://marketpublishers.com/r/GF96BE41D936EN.html>

Price: US\$ 3,660.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/GF96BE41D936EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970